Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVXNASDAQ:APGENASDAQ:IDYANASDAQ:KNSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$7.05+6.0%$6.62$4.77▼$14.16$421.97M0.01158,158 shs180,531 shsAPGEApogee Therapeutics$42.99-1.3%$38.97$26.20▼$63.50$2.01B1.38554,353 shs411,488 shsIDYAIDEAYA Biosciences$22.01+1.1%$19.86$13.45▼$44.42$1.91B0.041.03 million shs871,565 shsKNSAKiniksa Pharmaceuticals International$28.38-2.3%$26.47$17.38▼$30.69$2.12B0.06519,008 shs584,625 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+8.84%+9.74%+17.28%-6.21%-51.67%APGEApogee Therapeutics+5.32%+4.54%+10.31%+8.50%+11.67%IDYAIDEAYA Biosciences+1.68%-0.64%+15.73%+24.89%-41.14%KNSAKiniksa Pharmaceuticals International+1.18%+3.97%+8.07%+27.68%+54.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVXAbivax1.4594 of 5 stars3.52.00.00.00.00.80.6APGEApogee Therapeutics1.7639 of 5 stars3.51.00.00.00.04.20.0IDYAIDEAYA Biosciences3.3651 of 5 stars3.52.00.04.40.01.70.0KNSAKiniksa Pharmaceuticals International3.1933 of 5 stars3.53.00.00.02.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 3.00Buy$31.00339.72% UpsideAPGEApogee Therapeutics 3.00Buy$94.60120.05% UpsideIDYAIDEAYA Biosciences 2.93Moderate Buy$54.27146.58% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$38.8036.72% UpsideCurrent Analyst Ratings BreakdownLatest ABVX, KNSA, APGE, and IDYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.004/30/2025ABVXAbivaxJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.004/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.004/16/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/AAPGEApogee TherapeuticsN/AN/AN/AN/A$15.92 per shareN/AIDYAIDEAYA Biosciences$7M275.38N/AN/A$12.25 per share1.80KNSAKiniksa Pharmaceuticals International$423.24M4.89N/AN/A$6.60 per share4.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/A8/11/2025 (Estimated)APGEApogee Therapeutics-$182.15M-$3.60N/AN/AN/AN/A-28.35%-26.98%8/11/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.59N/AN/AN/AN/A-29.28%-27.68%8/5/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M-$0.25N/A113.52N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)Latest ABVX, KNSA, APGE, and IDYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/22/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.08N/AN/AN/AN/AN/A5/12/2025Q1 2025APGEApogee Therapeutics-$1.19-$0.95+$0.24-$0.95N/AN/A5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals International$0.02$0.11+$0.09$0.11$128.35 million$137.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AAPGEApogee TherapeuticsN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivax1.291.251.25APGEApogee TherapeuticsN/A15.8215.82IDYAIDEAYA BiosciencesN/A13.9213.92KNSAKiniksa Pharmaceuticals InternationalN/A3.663.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%APGEApogee Therapeutics79.04%IDYAIDEAYA Biosciences98.29%KNSAKiniksa Pharmaceuticals International53.95%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AAPGEApogee Therapeutics42.77%IDYAIDEAYA Biosciences2.50%KNSAKiniksa Pharmaceuticals International53.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6163.45 millionN/ANot OptionableAPGEApogee Therapeutics9146.05 million26.35 millionOptionableIDYAIDEAYA Biosciences8087.58 million85.39 millionOptionableKNSAKiniksa Pharmaceuticals International22072.97 million33.95 millionOptionableABVX, KNSA, APGE, and IDYA HeadlinesRecent News About These CompaniesKiniksa Pharmaceuticals International PLC - KNSA | Barron'sJune 24 at 10:23 PM | barrons.comKiniksa pharma COO Tessari sells $489k in sharesJune 19, 2025 | investing.comKiniksa pharma COO Tessari sells $489k in sharesJune 19, 2025 | investing.comEben Tessari Sells 17,300 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) StockJune 19, 2025 | insidertrades.comKiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Shares Bought by GAMMA Investing LLCJune 19, 2025 | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Sells 17,300 Shares of StockJune 18, 2025 | marketbeat.comKiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing FastJune 16, 2025 | seekingalpha.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Upgraded by Wall Street Zen to "Buy" RatingJune 15, 2025 | americanbankingnews.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Upgraded at Wall Street ZenJune 14, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Down 5.4% on Insider SellingJune 12, 2025 | marketbeat.comBarry D. Quart Sells 6,900 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockJune 12, 2025 | insidertrades.comBarry D. Quart Sells 6,900 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockJune 11, 2025 | marketbeat.comBarry D. Quart Sells 8,212 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockJune 11, 2025 | marketbeat.comEben Tessari Sells 10,319 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockJune 11, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Director Barry D. Quart Sells 12,336 SharesJune 11, 2025 | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells 15,506 Shares of StockJune 11, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $1,374,231.42 in StockJune 11, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 12,462 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)June 10, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Reaches New 1-Year High - What's Next?June 9, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock Position Raised by Wellington Management Group LLPJune 7, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Average Rating of "Buy" by AnalystsJune 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABVX, KNSA, APGE, and IDYA Company DescriptionsAbivax NASDAQ:ABVX$7.05 +0.40 (+6.02%) Closing price 04:00 PM EasternExtended Trading$7.04 0.00 (-0.07%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Apogee Therapeutics NASDAQ:APGE$42.99 -0.56 (-1.29%) Closing price 04:00 PM EasternExtended Trading$43.01 +0.02 (+0.05%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.IDEAYA Biosciences NASDAQ:IDYA$22.01 +0.23 (+1.06%) Closing price 04:00 PM EasternExtended Trading$22.02 +0.00 (+0.02%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Kiniksa Pharmaceuticals International NASDAQ:KNSA$28.38 -0.68 (-2.34%) Closing price 04:00 PM EasternExtended Trading$28.38 0.00 (-0.02%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
